CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?Zacks Investment Research • 10/14/25
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?Zacks Investment Research • 10/07/25
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYOGlobeNewsWire • 09/29/25
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?Zacks Investment Research • 09/23/25
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?Zacks Investment Research • 09/18/25
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?Zacks Investment Research • 09/15/25
CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 09/09/25
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the MarketPRNewsWire • 09/08/25
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a BetZacks Investment Research • 09/03/25
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?Zacks Investment Research • 09/02/25
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership TeamGlobeNewsWire • 09/02/25
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to TradeZacks Investment Research • 08/18/25
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry LeadershipBusiness Wire • 08/07/25
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care SettingsGlobeNewsWire • 08/07/25
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseZacks Investment Research • 08/06/25
Does CorMedix (CRMD) Have the Potential to Rally 65.64% as Wall Street Analysts Expect?Zacks Investment Research • 08/01/25